What Eli Lilly’s Kisunla Approval Means for Alzheimer’s Patients

In July of 2024, the FDA’s Center for Drug Evaluation & Research approved Donanemab, a novel Alzheimer’s treatment by pharmaceutical company Eli Lilly. Marketed as Kisunla, the new drug has shown promising results and its approval has been eagerly anticipated by patients, families, and healthcare providers worldwide.

Kisunla is a monoclonal antibody that targets and removes amyloid plaques, a key hallmark of Alzheimer’s (AD). By reducing amyloid buildup, Kisunla aims to slow down cognitive decline in early-stage AD patients. Clinical studies have shown that Kisunla can significantly slow cognitive decline in patients with early symptomatic AD, including patients with mild cognitive impairment (MCI) and mild dementia.

Kisunla’s approval represents a potential breakthrough in AD treatment. Where previous treatments have primarily focused on managing symptoms rather than addressing the underlying disease, Kisunla targets specific hallmarks of the disease.

Background

Alzheimer's is a progressive neurodegenerative disorder, affecting over 400 million people globally. Despite extensive research, effective treatments have remained elusive. The primary focus of AD research has centered on understanding the underlying pathological processes, including the formation of amyloid plaques and neurofibrillary tangles.

Kisunla works by targeting a specific type of amyloid beta protein, known as pyroglutamate amyloid beta, a key component of the amyloid plaques that build up in the brains of people with Alzheimer's disease.

Here's a breakdown of its mechanism:

• Amyloid Targeting: Kisunla is a monoclonal antibody, meaning it's a highly specific protein designed to bind to a particular target. In this case, it binds to pyroglutamate amyloid beta.

• Plaque Removal: Once bound, Kisunla helps to remove these amyloid plaques from the brain. This process is believed to slow down the progression of Alzheimer's disease.

By reducing the buildup of amyloid plaques, Kisunla aims to alleviate the damage caused by these clumps of protein and improve cognitive function in patients with early-stage Alzheimer's.

Note: While Kisunla addresses amyloid plaques, the exact mechanisms by which these plaques contribute to Alzheimer's disease are still being studied. While it’s known that the development of plaques disrupts neural communication and causes inflammation, it’s still an active area of research.

Implications

It’s crucial to note that Kisunla is not a cure for Alzheimer’s, and the drug’s long-term effects and impact on disease progression are still under investigation. Additionally, Donanemab has seen a higher rate of particular side effects in patients, including brain swelling, potentially raising concerns regarding the drug’s safety.

However, the approval offers hope to patients and their families, as Kisunla provides a potential treatment option for patients in the early stages of the disease. Further, the clinical success of Kisunla validates the amyloid hypothesis, a long-standing theory that amyloid plaques play a central role in AD pathogenesis, increasing support for further research into other amyloid-targeting therapies.

Accessibility

While Kisunla represents a significant advancement in Alzheimer's treatment, its accessibility is a complex issue. Several factors influence who can access the drug and how readily it can be obtained:

• Eligibility: Kisunla is currently approved for patients with early-stage Alzheimer's disease who have confirmed amyloid plaques. This means patients must undergo specific diagnostic tests to determine their eligibility.

• Insurance Coverage: The cost of Kisunla is likely to be high, and insurance coverage will vary. While some insurance plans may cover the drug, others may require prior authorization or have significant co-pays.

• Healthcare Provider Knowledge: Healthcare providers need to be aware of the drug, its benefits, and the eligibility criteria. Ensuring widespread knowledge among physicians is essential for patients to have timely access.

• Distribution and Supply: Adequate supply and efficient distribution channels are crucial for ensuring patients can receive the drug when needed.

The approval of Kisunla is a significant step forward, but Alzheimer's disease is a complex condition with multiple contributing factors. Ongoing research is exploring various issues in this space, including understanding diseases progression, risk factors, and early detection, as well developing novel therapeutic approaches (i.e. combination therapies, repurposing, immunotherapy, and neuroprotective methods)

While it's not a cure, clinical trials have shown promise in slowing cognitive decline in early-stage Alzheimer's patients, and Kisunla’s approval is a light of hope for patients globally.

©️ Copyright 2024 Healthcare Insights

All Rights Reserved

---

Legal Disclaimer:

The information provided in this article has been collected from various academic publications, industry reports/analyses, regulatory guidelines, media coverage, and legal analyses. The information provided is for general information purposes only and should not be construed for medical, legal, financial, or professional advice. Readers are advised to seek independent professional guidance where relevant. While we strive to ensure the accuracy and timeliness of our coverage, we claim no liability, representations, or warranties of any kind about the completeness, suitability, accuracy, reliability, authorship, or availability of this article and all pertaining data within this article. Neither the author nor the publication will assume liability for any loss or damage arising from the use of the information provided in the article. The information within this article may be outdated or inaccurate over time, and neither the author nor the publication are obligated to update or revise such information. We reserve the right to modify, remove, or substantially edit the article, including the disclaimer, at any time.

Photo Credit: Elil Lilly